Back to search

Article

Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with Attention-Deficit/Hyperactivity Disorder

2020-09-28

Abstract excerpt

<title>Abstract</title> <p><bold>Background </bold>Asverin<sup>®</sup> (tipepidine hibenzate) has been used as an antitussive for >50 years in Japan. Studies revealed that tipepidine modulates monoamine levels, by inhibiting G-protein-activated inwardly rectifying potassium (GIRK) channels, expecting the potential therapeutic effects of tipepidine for attention-deficit/hyperactivity disorder (ADHD) in recent year...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2384049b-6962-59ef-99fc-2fb9ff1a7613
DOI
10.21203/rs.3.rs-22945/v3
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with Attention-Deficit/Hyperactivity DisorderDOI 10.21203/rs.3.rs-22945/v3
Personalizing Atomoxetine Dosing in Children with ADHD: What Can We Learn from Current Supporting EvidenceSemantic proximity
Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.Semantic proximity
Evaluation of SLCA62 and CYP2D6 Polymorphisms’ Effects on Atomoxetine Treatment in Attention Deficit and Hyperactivity DisorderSemantic proximity
Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.Semantic proximity
Current Situation of Clinical Trials of Drugs for Children's Indications in ChinaSemantic proximity
Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.Semantic proximity
TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models.Semantic proximity
Ecopipam (EBS-101) as a Novel Non-D2 Therapy for Tourette Syndrome: A Systematic Review and Meta-analysis of Prospective Clinical StudiesSemantic proximity
Role of the norepinephrine transporter polymorphisms in atomoxetine treatment: From response to side effects in children with ADHD.Semantic proximity
Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disordersSemantic proximity
Cardiovascular Effects and Safety of Lisdexamfetamine in Attention-Deficit/Hyperactivity Disorder and Healthy Volunteers: A Systematic Review.Semantic proximity
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Verify the Efficacy and Safety of Ansofaxine (LY03005) for Major Depressive DisorderSemantic proximity
Select a neighboring publication to make it the new centre.